Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation

[1] Heise T(2014)Duration of action of 2 insulin glargine products, LY2963016 and Lantus, in subjects with type I diabetes mellitus (T1DM) Diabetes 63 A228-2233

[2] Zhang X(2015)Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies Diabetes Care 38 2226-733

[3] Lam ECQ(2015)Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus Diabetes Obes Metab 17 726-741

[4] Linnebjerg H(2015)) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study Diabetes Obes Metab 17 734-168

[5] Lam EC(2016)Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus Diabetes Obes Metab 18 159-999

[6] Seger ME(2017)) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study) Diabetes Care 40 994-510

[7] Blevins TC(2016)Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus insulin glargine in patients with type 1 or type 2 diabetes mellitus Diabetes Care 39 502-284

[8] Dahl D(2014)The fallacy of average: how using HbA(1c) alone to assess glycemic control can be misleading Diabetes Res Clin Pract 105 273-1257

[9] Rosenstock J(2011)Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes Diabetes Care 34 1249-787

[10] Rosenstock J(2018)Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes Diabetes Ther 9 771-1506

[1] Heise T(2014)Duration of action of 2 insulin glargine products, LY2963016 and Lantus, in subjects with type I diabetes mellitus (T1DM) Diabetes 63 A228-2233

[2] Zhang X(2015)Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies Diabetes Care 38 2226-733

[3] Lam ECQ(2015)Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus Diabetes Obes Metab 17 726-741

[4] Linnebjerg H(2015)) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study Diabetes Obes Metab 17 734-168

[5] Lam EC(2016)Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus Diabetes Obes Metab 18 159-999

[6] Seger ME(2017)) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study) Diabetes Care 40 994-510

[7] Blevins TC(2016)Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus insulin glargine in patients with type 1 or type 2 diabetes mellitus Diabetes Care 39 502-284

[8] Dahl D(2014)The fallacy of average: how using HbA(1c) alone to assess glycemic control can be misleading Diabetes Res Clin Pract 105 273-1257

[9] Rosenstock J(2011)Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes Diabetes Care 34 1249-787

[10] Rosenstock J(2018)Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes Diabetes Ther 9 771-1506